-
公开(公告)号:US20230271974A1
公开(公告)日:2023-08-31
申请号:US18176651
申请日:2023-03-01
Applicant: AbbVie Inc.
Inventor: Aileen L. Pangan , Henrique D. Teixeira , Ayman D. Allian , Thomas B. Borchardt , Jayanthy Jayanth , Patrick J. Marroum , Fredrik Lars Nordstrom , Ahmad Y. Sheikh , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Peter T. Mayer , Ben Klünder
IPC: C07D487/14 , A61K47/38 , A61K47/12 , A61K31/4985 , A61K9/00 , A61K9/20
CPC classification number: C07D487/14 , A61K9/0053 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment(including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
-
公开(公告)号:US20230203050A1
公开(公告)日:2023-06-29
申请号:US18176653
申请日:2023-03-01
Applicant: AbbVie Inc.
Inventor: Aileen L. Pangan , Henrique D. Teixeira , Ayman D. Allian , Thomas B. Borchardt , Jayanthy Jayanth , Patrick J. Marroum , Fredrik Lars Nordstrom , Ahmad Y. Sheikh , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Peter T. Mayer , Ben Klünder
IPC: C07D487/14 , A61K47/38 , A61K47/12 , A61K31/4985 , A61K9/00 , A61K9/20
CPC classification number: C07D487/14 , A61K47/38 , A61K47/12 , A61K31/4985 , A61K9/0053 , A61K9/2013 , A61K9/2054 , A61K9/2027 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment(including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
-
公开(公告)号:US20210361647A1
公开(公告)日:2021-11-25
申请号:US17115833
申请日:2020-12-09
Applicant: AbbVie Inc.
Inventor: Roopal B. Thakkar , Steven Jungerwirth , Ana Paula Machado de Lacerda , Ann M. Robinson , Jose Jeffrey V. Enejosa , Aileen L. Pangan , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klunder , Ayman D. Allian
IPC: A61K31/4985 , A61K31/495 , A61P1/00 , A61K9/00 , A61K9/48
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
-
公开(公告)号:US20180298016A1
公开(公告)日:2018-10-18
申请号:US15954039
申请日:2018-04-16
Applicant: AbbVie Inc.
Inventor: Aileen L. Pangan , Henrique D. Teixeira , Ayman D. Allian , Thomas B. Borchardt , Jayanthy Jayanth , Patrick J. Marroum , Fredrik Lars Nordstrom , Ahmad Y. Sheikh , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Peter T. Mayer
IPC: C07D487/14 , A61K47/38 , A61K31/4985 , A61K9/00 , A61K47/12
CPC classification number: C07D487/14 , A61K9/0053 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
-
-
-